HPK1-IN-65
HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC50 value of HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC50 of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC50 of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research[1].
Product Specifications
UNSPSC
12352005
Target
HOXA; Interleukin Related; MAP4K
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
FC1=C(NC2=NC=C(Cl)C(NC3=C(NS(C)(=O)=O)C(N=CC=N4)=C4C=C3)=N2)C=C5C(CCN(C)C5)=C1
Molecular Formula
C23H22ClFN8O2S
Molecular Weight
528.99
References & Citations
[1]Huang W, et al., Discovery of highly selective and potent HPK1 inhibitors for cancer immunotherapy. Eur J Med Chem. 2026 Jan 15;302 (Pt 2) :118322.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-2; MAP4K1/HPK1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HSV1 (Herpes Simplex Virus Type I) ICP8 (HSVI/2045), CF647 conjugate, 0.1mg/mL
(R)-5-(4-(Benzyloxy)-3-hydroxybenzyl)dihydrofuran-2(3H)-one
FAM86A (EEF2KMT) (NM_201400) Human Recombinant Protein
